Europe Exports Its Future
The continent produces world-class technology companies. Then it transfers ownership of them — to investors who understand what controlling an asset is actually worth.
In September 2016, SoftBank acquired Arm Holdings, the Cambridge-based chip design company whose processor architecture runs in virtually every smartphone on the planet, for £24.3 billion. The British government raised no serious objection. SoftBank promised to keep the headquarters in Cambridge and double the UK headcount. Seven years later, when Arm went public again, it listed not in London but on NASDAQ, at a valuation of $54.5 billion. The asset had more than doubled. The equity was now firmly in American markets. Britain retained the engineers, the office leases, and the tax receipts on salaries. It no longer held the claim on what Arm would be worth in 2030.
Arm is not a cautionary tale. It is the operating model.
· · ·
The standard diagnosis of Europe’s technology problem runs as follows: the continent produces talented engineers and promising startups, but cannot scale them into global companies because its markets are fragmented, its regulation is hostile, and its risk culture too conservative. Draghi said it. The European Commission has been saying it in various formulations since the dot-com era.
The diagnosis identifies a real constraint. It mislocates the primary failure.
Europe’s problem is not that it cannot build technology companies. It is that at the moment those companies become genuinely valuable, ownership transfers — to American funds, American acquirers, or American exchanges — and the control rights over future investment, expansion, and strategy transfer with it. A European researcher develops a technology. A European startup commercializes it. An American fund provides the growth capital, on terms that embed American exit expectations. An American exchange or acquirer provides the liquidity event. The equity, meaning the claim on future earnings and the right to direct how they are deployed, ends up in California or New York.
Europe retains the wages. It transfers the compounding.
· · ·
This exit structure is not a founder preference or a cultural failure. It reflects a capital allocation system that makes it structurally rational for European long-term investors to finance American markets rather than European growth assets.
Under Solvency II, the EU’s regulatory framework for insurers, unlisted private equity carries a standard capital charge of 49%, compared to 39% for listed equities in deep, liquid markets. At that differential, holding growth-stage stakes in European technology companies requires nearly half the invested amount to be set aside as regulatory capital. European insurers allocate a fraction of a percent of their total assets to private equity — a share that has remained near zero for a decade despite repeated policy efforts to change it, and roughly half the share that pension funds deploy, despite comparable liability horizons. The institutional capital that should be the natural long-term shareholder of European technology companies is, by regulatory construction, pointed elsewhere.
Where it goes is not hard to trace. American equity markets are deeper, more liquid, and carry no equivalent capital penalty for institutional holders. A European insurer optimizing its Solvency II position rationally overweights US listed equities. European long-term savings flow into American capital markets, which return to Europe as acquisition finance — on terms that transfer ownership outward. Europe provides the savings and the early-stage risk. The control rights move in one direction.
· · ·
ASML, SAP, and Adyen demonstrate that European capital can retain technology companies at scale. What they share is that each operates in a sector where technological irreplaceability or deeply embedded customer relationships make foreign acquisition unattractive. ASML makes lithography machines no one else can manufacture. Its ownership is partly European not because the capital markets functioned correctly, but because the product provides a structural exemption from the normal exit logic. That exemption is not available to most European technology companies, and it cannot be manufactured by policy.
The Capital Markets Union has been official EU policy since 2015. Eleven years of roadmaps have produced incremental harmonization of prospectus rules and marginal improvements in cross-border fund distribution. The gap persists because closing it requires member states to surrender national financial preferences — their domestic exchanges, their banking champions, their regulatory autonomy — that none has been willing to part with. France does not want Frankfurt setting the terms. Germany does not want Paris. The result is 27 partial markets instead of one deep one, and a venture capital ecosystem that remains structurally underweight in the late-stage categories where ownership is actually determined.
The Commission’s preferred response is more innovation policy: larger grants, deeper public funding, more startup support programs. Producing more startups for foreign capital to acquire at scale is not an industrial strategy. It is a subsidy program for foreign acquirers.
· · ·
THE VERDICT
Europe does not have a technology problem. It has an ownership problem, and the two require entirely different solutions. The Solvency II capital charge on unlisted equity is not a conspiracy against European technology. It encodes a political choice — policyholder protection over productive investment — that member states have made and could unmake. The Capital Markets Union has been a roadmap for eleven years because what it actually requires is that France, Germany, and Poland give up the national financial architecture each has spent decades protecting. More innovation funding is the answer that avoids that question. Europe has been choosing it since 2015, and the equity keeps leaving.